Concomitant illnesses in patients with diabetes: Mortality, morbidity, benefits of newer treatments, and individual and societal costs

Irina Farquhar; Alan Sorkin; Kent Summers; Earl Weir

doi:10.1016/S0194-3960(01)14009-6

Login

Welcome:
Guest

Search for:

Browse:

Product Information:

Resources:

Research in Human Capital and Development

ISSN: 0194-3960
Series editor(s): Professor Irene Farquhar

Subject Area: Human Resource Management

Content: Series Volumes | Current Volume RSS

Options: To add Favourites and Table of Contents Alerts please take a Emerald profile

Document request:
Concomitant illnesses in patients with diabetes: Mortality, morbidity, benefits of newer treatments, and individual and societal costs

Document Information:
Title:	Concomitant illnesses in patients with diabetes: Mortality, morbidity, benefits of newer treatments, and individual and societal costs
Author(s):	Irina Farquhar, Alan Sorkin, Kent Summers, Earl Weir
Volume:	14 Editor(s): Irina Farquhar, Kent Summers, Alan Sorkin ISBN: 978-0-76230-697-8 eISBN: 978-1-84950-070-8
Citation:	Irina Farquhar, Alan Sorkin, Kent Summers, Earl Weir (2001), Concomitant illnesses in patients with diabetes: Mortality, morbidity, benefits of newer treatments, and individual and societal costs, in Irina Farquhar, Kent Summers, Alan Sorkin (ed.) Investing in Health: The Social and Economic Benefits of Health Care Innovation (Research in Human Capital and Development, Volume 14), Emerald Group Publishing Limited, pp.197-281
DOI:	10.1016/S0194-3960(01)14009-6 (Permanent URL)
Publisher:	Emerald Group Publishing Limited
Article type:	Full length article
Abstract:	We study changes in age-specific diabetes-related mortality and annual health care utilization. We find that half of the estimated 16% increase of diabetic mortality falls within employable age groups. We estimate that disease combination-specific increase in case fatality has resulted in premature diabetic mortality costing $3.2 billion annually. The estimated annual direct cost of treating high-risk diabetics reaches $36 billion, of which Medicare and Other Federal Programs compensate 54%. Respiratory conditions among diabetics comprise the same proportion of high-risk diabetics as do the disease combinations including coronary heart diseases. Treating of general diabetic conditions has become more efficient as indicated by the estimated declines in per unit health care costs.